HFB3010

**HFB3010** is HiFiBiO Therapeutics' next-generation **OX40 agonist monoclonal antibody** for cancer immunotherapy. Public HiFiBiO materials indicate that the clinical development candidate associated with this program is **HFB301001**, now also referred to as **Nuvustotug**, a fully human IgG1 anti-OX40 antibody designed to activate the OX40 costimulatory pathway on activated T cells and enhance anti-tumor immune responses. The program has been developed for **advanced solid tumors** and entered **Phase 1** clinical testing after earlier preclinical disclosures referred to the broader program as HFB3010.

Brand names

Nuvustotug

Other names

anti-OX40 agonist monoclonal antibody HFB301001anti-OX-40 agonist monoclonal antibody HFB301001anti-OX 40 agonist monoclonal antibody HFB301001